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Introduction
The 2014 International Congress of the European Respiratory Society (ERS) in Munich, Germany,
included a substantial paediatric programme, with numerous high-quality scientific communications. As
for the 2013 Annual Congress [1], the chairs of the scientific groups of the Paediatric Assembly have
selected and discussed the most important abstracts to give a review of the research presented during the
meeting. Due to the large number of abstracts, this update cannot be comprehensive but aims to address
schemes of research in major areas of paediatric respiratory medicine.
Paediatric respiratory physiology and sleep
Forced oscillations
Several researchers have investigated how to apply the forced oscillation technique (FOT) clinically and
previous publications have provided technical recommendations for adults and children [2, 3]. In a study
designed to evaluate lung function using impulse oscillometry (IOS) and spirometry, UYAN et al. [4]
followed 41 children with post-infectious bronchiolitis obliterans (mean±SD age 8.8±5.0 years) for a
median of 29 months in three different centres in Turkey. Among the 26 subjects who were able to
perform spirometry, percentage of predicted respiratory system resistance (Rrs) at 5, 10, 15 and 20 Hz and
resonance frequency correlated negatively with forced expiratory volume in 1 s (FEV1), whereas reactance
values correlated positively with FEV1 results, suggesting that IOS, which requires only minimal
cooperation, is suitable for evaluating lung function in children with bronchiolitis obliterans. IOAN et al. [5]
proposed using FOT at a single frequency to detect the paradoxical glottis adduction during inspiration
that underlies the clinical manifestations of vocal cord dysfunction (VCD). Six children with VCD and 36
controls with asthma underwent a bronchial challenge and the investigators measured the difference
between inspiratory and expiratory Rrs (Rrsi−e). Rrsi−e in children with VCD versus controls was lower
at baseline than after the challenge (0.51±2.0 versus −0.37±1.0 hPa·s·L−1 (p<0.03) and 6.0±5.0 versus
−0.5±1.0 hPa·s·L−1 (p<0.001)), confirming that FOT can detect vocal cord adduction during inspiration in
children with VCD, a pattern that was exacerbated during the bronchial challenge. To assess whether a
modified FOT (wave-tube FOT) could be used to measure respiratory mechanics, GRAY et al. [6] studied
219 unsedated infants aged 6–10 weeks enrolled in a birth cohort study in South Africa. A total of 198
(90%) infants had successful measurements. Sex was a determinant of Rrs (higher in males) and
compliance (Crs) (lower in males), and Crs was significantly affected by maternal smoking during
pregnancy. These data suggest that the modified FOT is a feasible method for measuring respiratory
mechanics in healthy unsedated infants and might also be used for assessing lung function early in life.
Multiple-breath washout
Many researchers presented abstracts on the multiple-breath inert gas washout (MBW), a technique
addressed in a recently published technical consensus statement [7]. YAMMINE et al. [8] compared the
repeatability of shortened protocols to measure the lung clearance index (LCI) (calculated at 5% of initial
nitrogen washout) and standard LCI (calculated at 2.5% of initial nitrogen washout) in a longitudinal
sample of 37 children with CF (age range 5.7–7.2 years) over 35 months. Both indexes yielded similar
intra-test, mid-term (<4 months) and long-term (>4 months) repeatability. The authors also showed
nonsignificant mean changes after intravenous antibiotics. These data suggest that LCI at 5% of initial
nitrogen washout might be useful as a potential study end-point. To explain their previous finding that
nitrogen equipment (N2MBW) in younger children induced a higher LCI than sulfur hexafluoride
equipment with a mass spectrometer (SF6MBW), BENSELER et al. [9] evaluated the effects of equipment
dead space (VD) on LCI measurements. As previously reported, N2LCI was higher than SF6LCI in 10
healthy adults. When SF6MBW VD was increased to be equivalent to N2MBW VD, SF6LCI increased,
becoming higher than N2LCI, whereas when VD was added to the N2MBW system in steps approximating
1 mL·kg−1 to mimic the VD spectrum/weight ratios observed in preschool children, N2LCI increased
linearly by 0.4 units for each unit increase in weight-adjusted VD. These data suggest that the two methods
yield contrasting LCI values because their VD equipment differs and have important implications for
interpreting MBW data in young children. To obtain objective physiological assessments in children with
acute bronchiolitis, STAFLER et al. [10] measured LCI using SF6 and an ultrasonic flowmeter in 29 infants
with acute bronchiolitis (age 2.9±2.1 months) and 23 healthy controls (age 4.2±2.5 months). Valid tidal
breathing measurements were obtained in only 19 (66%) out of 29 infants with acute bronchiolitis and 15
of these achieved more than two valid MBW measurements, whereas valid tidal breathing measurements
were achieved in 22 (97%) out of 23 of the controls and 19 also achieved more than two valid MBW
measurements. LCI was 8.4±0.8 in infants with acute bronchiolitis and 7.3±0.7 in controls (p<0.001). In
five infants with acute bronchiolitis who returned after 4 months, LCI decreased from 8.3±0.9 to 7.4±0.7
(p=0.08). The authors concluded that measuring LCI in infants with acute bronchiolitis is feasible,
although technically challenging, and LCI can potentially serve as an objective severity measure. In a
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similar study, KOBBERNAGEL et al. [11] assessed the long-term variability in N2MBW indices in 26 children
(6–18 years) with primary ciliary dyskinesia (PCD) on three occasions during a 1-year follow-up. For LCI,
the within-occasion standard deviation (95% CI) was 0.63 (0.55–0.70) and the coefficient of variation was
6.6% (6.0–7.2%), whereas the between-occasion standard deviation was 1.08 (0.83–1.28) and coefficient of
variation was 11.4% (10.4–12.5%). The authors also reported within-occasion and between-occasion
variability for other MBW indices (Scond and Sacin), thus providing important information for using and
interpreting N2MBW indices in the clinical management of PCD in children and as outcome measures in
interventional studies.
Reference values
After the Global Lung Initiative (GLI) reference equations for spirometry were published in 2012 (GLI
2012) [12], researchers focussed on validating these equations in different populations and age groups.
ARIGLIANI et al. [13] performed spirometry in 399 children (202 boys) aged 6–12 years from two public
and two private schools in Ambanja, Madagascar. GLI 2012 equations for black people fitted well with
spirometric data for Malagasy children. FEV1 and forced vital capacity (FVC) were reduced in
malnourished children with no evidence of airflow limitation, reflecting stunted growth. Conversely,
IGLESIAS et al.[14] found that the GLI 2012 equations significantly overestimated FEV1 and FVC values in
318 white, healthy Spanish children aged 7–15 years, suggesting that the reasons for this discrepancy
should be investigated before applying the GLI 2012 equations in Spanish school-age children. Similarly,
KIRKBY et al. [15] found, in 811 healthy Indian children aged <12 years, that GLI 2012 significantly
underestimated FEV1 and FVC values, and calculated a new coefficient for Indian children. Focussing on
other lung function techniques, MANDADZHIEVA et al. [16] produced prediction equations for transfer factor
of the lung for carbon monoxide (TLCO) in 449 healthy Bulgarian children aged 7–18 years (254 boys).
Boys had significantly higher values for single-breath TLCO than girls (7.19±2.47 versus 6.51±1.71 mmol
min−1·kPa−1, p<0.001), while alveolar volume (VA) was similar in both sexes. TLCO and VA showed close
correlations with height (r2 between 0.82 and 0.90), and with increasing height, all children presented a
faster increase in TLCO and VA.
Functional monitoring of sleep disordered breathing
BOUDEWYNS et al. [17] assessed the usefulness of endoscopy under sedation as a tool to detect anatomical
factors for upper airway obstruction in 13 obese children with obstructive sleep apnoea (OSA) aged 9–
14 years. In the six surgically naïve children, endoscopy showed upper airway obstruction at the level of
the adenoids and tonsils with associated upper airway hypotonia in five, whereas in six out of seven
children with previous upper airway surgery, endoscopy documented partial or complete tongue base
obstruction, and in three out of four children with previous adenoidectomy, significant tonsillar
obstruction was seen. Endoscopy under sedation was reported to be a useful tool for obtaining insights in
the pathogenesis of OSA in obese children and making treatment decisions. Seeking ways to reduce the
need for polysomnography (PSG), PIETROPAOLI et al. [18] investigated whether a sleep clinical record (SCR)
and nocturnal pulse oximetry with a McGill Oximetry Score (MOS) could detect OSA. MOS yielded
positive results (>2) in 52 out of 285 children with a sensitivity of 20.5% and a specificity of 97.2% in
detecting OSA when compared with PSG, whereas 227 (79.6%) children had a positive SCR score (>6.5)
with a sensitivity of 81.1% and a specificity of 30.5%. In 48 (16.8%) children, all of whom received a
diagnosis of OSA at PSG, SCR and MOS in combination detected the presence of obstructive apnoea with
a sensitivity of 52% and a specificity of 100%. These findings suggest that SCR and nocturnal pulse
oximetry with MOS may offer a valid alternative to PSG. Finally, ALEXOPOULOS et al. [19] aimed to study
whether nocturnal enuresis (defined as urine incontinence on more than one night per week) was
associated with an increased risk of moderate to severe OSA (apnoea–hypopnoea index >5 episodes·h−1)
among 525 children with snoring (age 7.5±2.2 years) referred for PSG over 12 years. 355 (67.6%) children
had nocturnal enuresis and 87 (16.6%) had moderate to severe OSA. Nocturnal enuresis was associated
with moderate to severe OSA after adjustment for tonsillar hypertrophy, obesity, sex and age. Nocturnal
enuresis had a high sensitivity (78.2%) and a low positive predictive value (19.2%) for detecting moderate
to severe OSA, and a low specificity (34.5%) and a high negative predictive value (88.8%) for ruling it out,
suggesting that children with snoring and without nocturnal enuresis referred for PSG are less likely to
have OSA than those with nocturnal enuresis.
Paediatric asthma and allergy
Databases
“Big data” found its way into paediatric asthma. Although guidelines heavily rely on results from
randomised controlled trials, only few patients treated for asthma meet the eligibility criteria for major
trials [20]. MURRAY et al. [21] compared the effectiveness of adding a long-acting β-agonist (LABA) versus
increasing the dose of inhaled corticosteroids (ICS) in a real-life population of children whom low-dose
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ICS left uncontrolled. Patients (n=3129) were recruited from two UK databases. Increasing the dose of ICS
led to fewer exacerbations with similar asthma control than adding a LABA. These results provide no
support for the step 3 recommendations of the 2014 British Thoracic Society/Scottish Intercollegiate
Guidelines Network and Global Initiative for Asthma (GINA) guidelines on asthma management, and this
gap between guidelines and implementation is exactly what MURRAY et al. [22] showed in a second
presentation from the same study.
Seeking further information an asthma management, ENGELKES et al. [23] used a large general practitioners’
database to identify children with asthma and studied severe asthma exacerbations in this group of
patients. The overall rate of severe exacerbations was 0.02 per year, being highest in children <7 and
>15 years of age, and in children on ICS who were treated by a paediatrician. A history of severe
exacerbations increased the risk of subsequent severe exacerbations, a finding in line with earlier studies
[24]. In a separate study, ENGELKES et al. [25] found that LABA monotherapy was decreasing but, despite
the guidelines, the prevalence remains at 1.44 per 100 per year. Although few studies have addressed
clinical effectiveness in childhood asthma, research of this kind gives a major insight into the problem and
may be complimentary to the results reported in randomised controlled trials.
Preschool wheeze
Preschool wheeze remains a topic of high clinical and scientific interest. Much effort has focussed on
defining the clinical phenotypes that warrant different treatment or monitoring strategies, and on
predicting asthma at school age [26]. MUTTI et al. [27] were unable to distinguish preschool children with
episodic viral wheeze (EVW) from children with multiple-trigger wheeze (MTW) by clinical and
endobronchial biopsy results, suggesting a similar pathophysiology for both entities. They did, however,
find thicker basal membranes and more epithelial loss, and higher mucosal eosinophil and mast cell
numbers in children with wheeze compared to controls. These results are supported by animal data and
data from autopsy studies presented by ANDERSSON et al. [28] showing that increased mast cells in the
alveolar parenchyma after respiratory viral infections may affect susceptibility towards allergens and
asthma development in later life. The biopsy data provided by MUTTI et al. [27] might imply that asthma
is as likely to develop in children with EVW as in those with MTW. In preschool children, others found
no difference in reticular basement membrane thickness and mucosal eosinophils or airway smooth
muscle mast cell values between children who did or did not have asthma at school age, but they made no
distinction between preschool children with MTW and EVW [29]. Yet, biopsy studies, in general, include
highly selected populations of children who had a clinical indication for bronchoscopy. GOKSÖR et al. [30]
nevertheless showed a higher risk of doctor-diagnosed asthma at 8 years for children with EVW and
MTW than for children without preschool wheeze (MTW: OR 48.9, 95% CI 29.3–81.6; EVW: OR 16.2,
95% CI 10.3–25.6). This risk was independent of atopic heredity and allergic sensitisation during
preschool years. These data showed that many children with EVW will continue to wheeze and will have
asthma, suggesting that EVW is not always a transient, “innocent” disease. In an attempt to define
asthmatic and preschool wheezing phenotypes in an unbiased clustering of children, BRINKMAN et al. [31]
used an electronic nose (eNose) platform and, with a metabolomics approach, the researchers identified
five clinical clusters, which differed in age, atopic state, asthma control and asthma-related quality of life
(fig. 1). Whether these five clusters are clinically meaningful and can guide management remains unclear.
In a study by VAN DER SCHEE et al. [32], the eNose was also able to discriminate atopic wheeze from
nonatopic wheeze in a small cohort of 64 patients, with moderate accuracy (area under the curve 0.74,
p=0.008). Another possible source of noninvasive and easily obtainable inflammatory biomarkers in
preschool children is urine. CHIU et al. [33], in a birth cohort study, showed that elevated urinary
leukotriene E4 had a high specificity and a high positive predictive value for asthma and rhinitis after age
Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5
FIGURE 1 Topology clusters of asthma
patients identified using an eNose
platform. Reproduced from [31] with
permission from the authors.
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2 years. These data suggest that biomarkers in the urine may have an added value in diagnosis and
monitoring of preschool children.
Several groups showed that preschool wheeze and asthma have a multifactorial aetiology that includes
viruses (in particular rhinovirus) [34], traffic-related air pollution [35], prenatal exposures to environmental
contaminants [36], foods and genetics. LUKKARINEN et al. [34], in a cohort of 64 infants hospitalised for their
first wheeze episode, showed that rhinovirus detection and allergic sensitisation were the most important risk
factors for atopic asthma at age 7 years, but not for nonatopic asthma. Current evidence therefore confirms
that rhinovirus interacts with atopy and with immune system maturity in the development of asthma. The
mechanisms underlying rhinovirus-induced wheeze now need unravelling in prospective studies of
rhinovirus infections in asymptomatic, healthy preschool children [37]. SHULTZ et al. [35], reporting results
from the BAMSE cohort study, showed that exposure to air pollution from road traffic, especially during the
first year of life and between years 1 and 8, was associated with impaired small airway function as measured
by IOS in adolescents. Their data conflicted with the results reported by OLSSON et al. [38], who failed to find
a higher risk of asthma after prenatal exposure or exposure during infancy to air pollution. These
discrepancies may depend on differences in how exposure to air pollution was measured and in the
outcomes used. Similarly, SMIT et al. [36] found only very limited evidence linking prenatal exposure to
contaminants to asthma and eczema in school-age children in Ukraine and Greenland. Obviously, such an
association needs assessment in more studies on different exposures and in different populations.
Previous studies have shown that preterm birth, low birth weight and high infant weight gain are associated
with increased risk of later asthma development. To investigate these possible risks, DUIJTS et al. [39]
collected data from 24 birth cohorts to assess the association of early growth and lung function. Preterm
birth (<37 weeks) had an adverse effect on FEV1/FVC and forced expiratory flow at 75% of FVC (FEF75%),
and low birth weight (<2500 g) on FEV1, FVC and FEF25–75%. The authors concluded that smaller airways
might be partly responsible for the associations between early growth characteristics and asthma.
Monitoring of asthma
During the International Congress, the ERS Task Force on Monitoring of Asthma in Children presented
their results. Clinical history, spirometry, and assessment of adherence to therapy, inhaler technique and
exposures remain the mainstays of monitoring of asthma [40]. The Task Force members found no
evidence supporting the use of composite asthma control scores and asthma-related quality of life or
symptom diaries in daily practice. Future directions in monitoring of asthma should include monitoring
strategies in specific populations, also called “phenotyped” or “personalised” monitoring. VAN BRAGT et al.
[41] in a randomised controlled trial enrolling 93 school children with asthma showed that adding an
individualised self-management support programme to usual care resulted in better asthma-related quality
of life. Personalised monitoring strategies could usefully include biomarkers in blood, urine, sputum or
exhaled breath, genetic markers, and electronic health initiatives.
Cystic fibrosis
Therapies
Cystic fibrosis transmembrane conductance regulator therapies
In the past years, the most exciting new therapies for cystic fibrosis (CF) have focussed on small-molecule
therapy, to correct or potentiate the faulty or missing chloride channel on epithelial cell surfaces. The initial
studies on the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator ivacaftor in patients
with the p.Gly551Asp mutation showed an impressive reduction in sweat chloride, accompanied by a
significant improvement in lung function, weight gain and quality of life [42]. Greater clinical experience
with the drug has resulted in publication of post-marketing experience in 151 children aged 6 years and
above [43]. The hospitalisation rate decreased by 19%, thus improving this expensive drug’s health
economic evaluation. Pseudomonas aeruginosa growth decreased, mucociliary clearance doubled and
microbial diversity increased. Additionally, intestinal bicarbonate secretion increased (and gut pH increased
by 1.5), which may explain the observed improvement in weight gain. A recent publication has extended
safety and efficacy data to 144 weeks, and showed maintained improvements and good tolerance [44].
Data have now been published on the use of ivacaftor for the other nine, much rarer (non-p.Gly551Asp)
gating mutations that have shown encouraging effects (apart from the p.Gly970Arg mutation) on sweat
chloride, lung function, nutrition and quality of life [45].
Ivacaftor has been studied in combination with the CFTR corrector lumacaftor in patients homozygous for
the p.Phe508del mutation. The results from the phase 2 studies were published last year [46].
Ataluren is a drug that leads to the production of full-length CFTR protein in patients with nonsense
mutations (e.g. p.Gly542X). Last year saw the publication of the phase 3, 48-weeks study in 236 patients
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over 6 years old [47]. The results were disappointing after the drug had shown early promise; however,
post hoc analysis showed a positive effect in patients not taking inhaled tobramycin.
Antimicrobial therapies
Some important publications have addressed antibiotic therapy. A phase 2 trial of inhaled Arikace, a
liposomal amikacin preparation for nebulisation, showed, in 105 patients after 28 days treatment, a
significant rise in FEV1, which was maintained (although to a lesser extent) after a month off therapy [48].
In an open-label extension, lung function also improved with 28 days of therapy followed by 56 days off;
this was accompanied by a reduction in sputum P. aeruginosa density [48]. This should offer another
inhaled antibiotic option for treating chronic P. aeruginosa infection. At the ERS International Congress,
BILTON et al. [49] presented interim data from the CLEAR-110 extension study in which long-term safety,
tolerability and efficacy of once-daily liposomal amikacin (in monthly on–off cycles) is being studied in
over 200 patients for 2 years. The treatment was well tolerated and improvements in lung function were
maintained during both the on and off treatment months.
Another study published last year looked at patients with Burkholderia infection, who are usually excluded
from trials [50]. The study investigated the use of inhaled aztreonam in 105 children and adults with
chronic Burkholderia infection, and found no significant improvement in lung function, hospitalisation
rate or chest exacerbations, with a trend for less antibiotic use. Unfortunately, it was a negative study, but
at least it was published, given the definite bias towards publishing only positive results [51].
As well as nebulised antibiotics, some pharmaceutical companies have introduced dry powder forms. Inhaled
colistimethate sodium is now being given for chronic P. aeruginosa infection in a dry powder form because it
is quicker to administer than the traditional nebulised form and may therefore improve adherence. SU et al.
[52] used radioactive scintigraphic imaging to look at lung and oropharyngeal deposition, and found that the
dry powder gave a greater lung deposition than the nebuliser (12% versus 6%).
Nebulised mannitol is a recently introduced mucoactive osmotic agent [53]. ONG et al. [54] reported that
in vitro the drug promotes P. aeruginosa dispersion from the biofilm and enhances the antibacterial effect
of ciprofloxacin (fig. 2). This may add to the benefit of this treatment. The study also demonstrated a
model for studying bacterial biofilms.
Azithromycin has become a standard part of therapy in CF, used both in the long term as well as for
shorter antibiotic courses. Respiratory viral infections play an important role in CF lung disease, with few
specific therapies available. SCHOEGLER et al. [55], in an in vitro study, showed that azithromycin
pre-treatment reduced rhinovirus replication seven-fold in bronchial epithelial cells, although it did not
prevent rhinovirus-induced cytokine production. This suggests that azithromycin may have an antiviral
role and, in their recent full publication, the authors suggest that studies are necessary to see whether
azithromycin might have a role in preventing or managing rhinovirus exacerbations in CF [56].
Influenza immunisation has been recommended for people with CF for many years. For the winter of
2013–2014, the US CF Foundation stated that the new live attenuated influenza vaccine delivered as a
nasal spray was contraindicated in CF, due to a lack of data. A safety study has now been published in 168
CF patients aged 2–18 years receiving FluMist (MedImmune, Gaithersburg, MD, USA) [57]. There was no
increase in respiratory deteriorations or hospitalisation for 28 days post-immunisation, although 8% of the
patients did wheeze in the first week (two thirds on the actual day). This should allow its use in children
with CF, which will help those with needle anxiety. Contraindications remain immunosuppression
(including oral corticosteroids), acute wheezing on the day and large nasal polyps.
Local drug deposition 
on biofilm
No drug deposition
FIGURE 2 Scanning electron micrographs of a) the nonhomogeneous codeposition of ciprofloxacin and mannitol on the biofilm, b) the site of aerosol
deposition and c) areas of no drug deposition. Scale bars=2 μm. Reproduced from [54] with permission from the authors.
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Other therapies
Intravenous aminophylline is sometimes used during chest exacerbations, especially when the patient has a
tight chest with severe bronchoconstriction. WADDINGHAM et al. [58] reviewed their use in 30 patients. 60%
had subtherapeutic levels; only 0.4% levels were high. Although adverse effects were common (60%), none
led to drug cessation. The investigators suggested that high doses are required to reach therapeutic levels.
Finally, vitamin D deficiency is common but the levels recommended for optimising bone mineralisation
(75–150 nmol·L−1) are hard to achieve in CF. MISTRY et al. [59] reviewed their prescribing practice and
found that, initially, many patients were not receiving the correct daily dose. As expected, adherence was a
major issue. Vitamin D seems to have a role in many things and is the subject of a profusion of
publications. SCHOEGLER et al. [60] in an in vitro study showed that vitamin D lowered rhinovirus 16
replication in bronchial epithelial cells, possibly by inducing the antimicrobial peptide cathelicidin.
Assessment of disease
The LCI measures ventilation inhomogeneity and has been shown to be a useful marker of early CF lung
disease. It is also one of the more sensitive outcome measures available for clinical trials; for example, the
LCI decreased by a mean of 2.2 in 21 patients receiving ivacaftor [61]. ELBORN et al. [62] showed an
association of a raised LCI with systemic inflammation (C-reactive protein and white-cell count);
HATZIAGOROU et al. [63], an association with a positive sputum culture and chest exacerbations; and
GROSSE-ONNEBRINK et al. [64], LCI as a predictor of future exacerbations. Although the LCI was also
associated with computed tomography (CT) findings of bronchiectasis in children (excluding infants),
RAMSEY et al. [65] suggested that it is not a substitute for a chest CT but has a role as a surveillance tool.
Chest CT scanning has its advocates, although many believe its role should be restricted to clinical need
on an individual basis rather than routine annual surveillance. CT scores for bronchiectasis may be useful
in more advanced disease, but in mild cases, scoring is less helpful. The publication from the London CF
Collaboration newborn screened cohort illustrated this disadvantage by showing that CT changes in
1-year-olds had poor to fair agreement between two scorers (best for air trapping), probably because the
changes were very mild (especially compared with the Australian AREST-CF data) [66, 67]. ROSENOW et al.
[68] reported on a new imaging technique, PRAGMA (Perth–Rotterdam Annotated Grid Morphometry),
which is said to have good inter- and intraobserver agreement in young children. BOON et al. [69] used CT
scans of explanted lungs, including micro-CT on lung tissue cores, to study end-stage lung disease.
Magnetic resonance imaging
The radiation burden of CT scans has aroused increasing interest in the use of magnetic resonance
imaging (MRI) for long-term monitoring of lung disease. JUNG et al. [70] reported that typical findings in
children with CF can be demonstrated and dynamic contrast-enhanced imaging reveals lung perfusion
abnormalities, which may differentiate chronic consolidation from acute atelectasis due to sedation.
MARSHALL et al. [71] reported that early lung changes, including those in subclinical disease, can be
detected using hyperpolarised helium MRI, and that this technique was more sensitive than LCI, lung
function and proton MRI (fig. 3).
Inflammatory markers
If assessed noninvasively, inflammatory markers could be used routinely and repeatedly. PAREKH et al. [72],
in a pilot study, looked at several urinary biomarkers and found higher levels of the protease inhibitors
TIMP2 (tissue inhibitor of metalloproteinase) and α1-antitrypsin, and lower levels of fMLP
(formyl-methionyl-leucyl-phenylalanine), a neutrophil chemotactic agent, in patients with CF compared to
healthy volunteers. More work is needed to determine whether these markers will have any clinical use.
Elafin is a serine elastase inhibitor and therefore has anti-inflammatory properties. YACOB et al. [73]
measured significantly lower plasma elafin levels in children with CF (who were free from exacerbation)
than in controls, whereas elastase levels were comparable in the two groups. The authors concluded that
although elafin replacement therapy may be effective, much work remains to be done before this
possibility can be considered. Using automated proteomic technology, DEBOER et al. [74] analysed over
1100 proteins in bronchoalveolar lavage fluid, to assess whether they may be biomarkers for bronchiectasis
on a CT scan; 82 proteins correlated significantly with the CT airway score but no adjustment was made
for multiple comparisons. As many as 43 of these proteins correlated more strongly than neutrophil
elastase with the airway score.
Miscellaneous
With increasing survival and a known increased risk of gastrointestinal malignancy, the adult centre in
Munich has instituted screening colonoscopy at 40 years of age (routine screening is recommended at
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55 years in Germany). NAEHRIG et al. [75] found a high rate of abnormalities in 11 patients studied (two
adenocarcinomas, three tubulovillous adenomas and one patient with an inflammatory polyp.
The CF-ABLE score (based on age, body mass index (BMI), lung function and number of exacerbations)
has been developed as a prognostic tool. MEURLING et al. [76] showed that the score predicts death or
transplantation over a 4-year period.
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FIGURE 3 Images from five different patients with mild cystic fibrosis: hyperpolarised helium magnetic resonance
imaging (MRI), computed tomography (CT) and proton MRI. Arrows indicate common features between MRI and CT.
Images courtesy of POLARIS, The University of Sheffield, Sheffield Children’s Hospital and the Cystic Fibrosis Trust.
Reproduced from [71] with permission from the authors.
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High cyanide levels have been found in the sputum of CF patients infected with P. aeruginosa and correlate
negatively with lung function. Recently, cyanide has been shown to impair mucociliary function in vitro
[77]. GILCHRIST et al. [78] evaluated exhaled breath hydrogen cyanide (HCN) measured by SIFT (selected
ion flow tube) mass spectrometry as a marker of P. aeruginosa infection in children. While raised HCN is a
marker of Pseudomonas infection, the sensitivity needs to be improved to make this a useful measure.
International guidelines and standards of care
The US CF Foundation Infection Control guidelines were updated in 2013 (published in 2014). Among
many suggestions, the guidelines recommend that staff should all wear gowns and gloves when in contact
with CF patients, and the patients themselves should wear facemasks when in the hospital environment
[79]. There may be quite an effect on patient morale in terms of stigmatisation and it would be a surprise
if many European centres fully adopted this approach.
The US CF 2014 guidelines also recommended keeping patients 2 m (6 feet) apart based on how far cough
aerosols travel. Since this publication, work from Australia has shown that after intense coughing for
5 min, P. aeruginosa can travel as far as 4 m (13 feet) and viable organisms remain in the air for 45 min
[80]. This observation proves, once again, that people with CF should stay apart and not mix socially with
each other.
The European CF Society Standards of Care were published as three separate documents, a framework for
a CF centre that describes what that centre needs in terms of facilities and multidisciplinary staffing [81];
practice guidelines outlining recommendations for clinical care and what CF centres should provide [82];
and quality management, which describes areas for quality improvement moving from an individual to
national and international levels [83].
Paediatric respiratory infection and immunology
The major cause of hospital admissions for acute respiratory symptoms during the first years of life is
bronchiolitis. To date, the efficacy of inhaled therapies for bronchiolitis remains unclear. This uncertainty
may account for the wide variation in approaches to treatment. For example, CONSTANT et al. [84], in a
survey including members of the Portuguese Society of Paediatrics (n=514) and general practitioners
(n=165), found that inhaled salbutamol was used by 43% of respondents for mild disease and by 78% for
moderate disease. 20% of paediatricians routinely used hypertonic saline for moderate disease. The routine
use of inhaled therapy was also reported by BON et al. [85], who compared bronchiolitis treatment in a
single Italian tertiary unit in 2002 and 2012. At both time-points, most infants received bronchodilator
therapy (72.4% in 2002 and 91.3% in 2012). However, a recent Cochrane review that included data from
30 trials representing 1992 infants with bronchiolitis found that bronchodilators do not improve oxygen
saturation, do not reduce hospital admission after outpatient treatment and do not shorten the duration of
hospitalisation [86]. The Cochrane review’s authors therefore concluded that “bronchodilators are not
effective in the routine management of bronchiolitis”.
Since there is good evidence to suggest that bronchodilators are ineffective in bronchiolitis, the efficacy of
hypertonic saline is of interest. MAGUIRE et al. [87] reported the results of a systematic review of controlled
trials of nebulised hypertonic saline for infants hospitalised with primary acute bronchiolitis. They
identified 15 trials representing 1722 infants. Overall, hypertonic saline reduced the mean length of stay in
the hospital by 0.41 (95% CI −0.56–−0.27) days, but the researchers found a risk of bias and high levels of
heterogeneity. Remarkably, no trial reported intervention-related severe adverse events. EVERARD et al. [88]
also reported the results of their own trial. This was a parallel-group, pragmatic randomised controlled
trial performed in 10 UK hospitals. Infants with acute bronchiolitis were randomised either to standard
supportive care with oxygen as required or to supportive care plus 6-hourly 3% nebulised hypertonic
saline. The primary outcome was the time to when infants were assessed as being “fit for discharge”,
defined as, in air with saturations of >92% for 6 h. 141 infants were allocated to hypertonic saline and 159
to standard care. There was no difference between the two arms in the time to being declared fit for
discharge (hazard ratio (HR) 0.95, 95% CI 0.75–1.20) or to actual discharge (HR 0.97, 95% CI 0.76–1.23).
There was also no difference in adverse events. In a separate trial, LOZA et al. [89] assessed the efficacy of
nebulised 3% and 6% hypertonic saline compared with normal saline in children hospitalised with
bronchiolitis. In this multicentre, randomised and double-blind controlled trial, 292 infants were
randomised to receive either nebulised 3% or 6% hypertonic saline, or normal saline during their hospital
stay. The primary end-point was length of hospital stay. Overall, no difference was found between the
three treatment groups in median length of hospital stay and adverse effects were similar in the three
groups. Since the UK trial conducted by EVERARD et al. [88] suggests that 3% hypertonic saline is
ineffective and the Dutch trial by LOZA et al. [89] suggests that the efficacy of 3% hypertonic saline is no
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different from either 6% hypertonic saline or normal saline, it is likely that all three inhaled saline
therapies are ineffective.
Despite recent evidence that inhaled therapies should not be routinely used in bronchiolitis, there may be
ways of improving the quality and efficiency of standard supportive care. First, BEKHOF et al. [90], in a
prospective cohort study, assessed the effect of cohorting respiratory syncytial virus (RSV)-positive infants
separately from RSV-negative infants. Infants shared a two- to four-bed hospital room during the entire
admission, irrespective of the virological diagnosis. Of the 65 infants, 94% were RSV positive, 56 (86%) of
whom shared a room with another bronchiolitis patient. 18 (28%) of these infants had bronchiolitis related
to another respiratory virus. On admission, 10 (15%) infants were already co-infected with another virus
and eight (12%) infants became cross-infected with a different virus during their admission. Of these
cross-infected infants, only one had shared a room with the virus identified in one of its roommates. Given
that there are no significant differences in disease severity between patients infected with single or multiple
viruses, nor between RSV-positive and RSV-negative patients, the researchers concluded that room sharing
does not seem to play a major role in the transmission of viruses between infants with bronchiolitis sharing
a room. Second, in an uncontrolled study, RUBIO et al. [91] reported that infants with bronchiolitis treated
with a high-flow nasal oxygen cannula did at least as well as infants given usual oxygen care. Indeed,
preliminary evidence showed a decreased risk of transfer to intensive care and no technical complications.
Neonatology and paediatric intensive care
Neonatology
Minimising lung injury and preventing the development of chronic lung disease continues to be a
challenge in the care of very preterm infants. Intensive research efforts now focus on seeking reliable
markers to predict short- and long-term lung morbidity. BARALDI et al. [92], in a pilot study, collected
amniotic fluid samples and performed metabolomic analysis, which revealed the presence of metabolic
profiles characterising preterm delivery and bronchopulmonary dysplasia (BPD) development. PRAMANA
et al. [93] reported that levels of pro-endothelin-1, a potent pulmonary vasoconstrictor, might serve as a
marker for severe lung injury and the development of BPD in very preterm infants. In established BPD,
DASSIOS et al. [94] showed that the chest radiographic thoracic area is significantly related to disease
severity as quantified by ventilation–perfusion inequality and oxygen requirement. HENCKEL et al. [95]
investigated the relationship between telomere length as a marker of previous oxidative stress,
chitinase-like protein YKL-40 as a marker of airway remodelling and lung function in school-age children
with a history of BPD. They found that BPD was associated with increased levels of YKL-40, which also
correlated with significantly shorter telomeres. The clinical progression of BPD and long-term lung health
in preterm infants are difficult to predict, as was demonstrated in a recent thorough systematic review and
an external validation study [96]. The aforementioned studies all help to advance research for better
predictive tools to be used in future intervention studies.
Understanding the many and complex causes driving the development of BPD is another challenge still
facing neonatologists, and is even more pressing now that survival is increasing even in the most extremely
immature gestational age groups [97]. Experimental evidence suggests that the bone morphogenic protein
(BMP) pathway participates in regulating pulmonary vasculogenesis, and might thereby intervene in the
development of pulmonary hypertension and chronic lung disease. In a mouse model of BPD, KOSCHLIG
et al. [98] showed that activating the BMP receptor II signalling pathway improved impaired vasculogenesis.
In another mouse model of hypoxia-induced pulmonary hypertension presented by MORENO et al. [99],
upregulation of the BMP antagonist Gremlin-1 was shown to contribute to increased vascular tone. Both
studies indicate that modulating the BMP signalling pathway may be a promising strategy to prevent
pulmonary hypertension in the newborn (PHN). This is also in line with recent experimental findings
showing that sildenafil, a treatment option increasingly used in PHN, potentiates BMP signalling [100].
The maturational changes in the immune system after preterm birth are still incompletely understood.
Immunological factors may play a role in the development of BPD during the perinatal period. Two
studies extended current knowledge on this relationship. MUSTAFAYEV et al. [101] evaluated cellular
immunity in patients with BPD and reported that the acute phase of the disease was characterised by
T-cell inhibition. FRANKENBERGER et al. [102] described a strong expansion and aberrant phenotype of
intermediate blood monocytes in preterm neonates related to the innate immune system immaturity.
Lung function testing in the neonatal period continues to be a rapidly expanding field. The importance of
an adequate diaphragm function for extubation success was investigated by BHAT et al. [103] who found
that tension time index measurements of the diaphragm may be useful in predicting extubation success in
term but not preterm neonates. The mechanism explaining why the prone sleeping position is a risk factor
for sudden infant death syndrome was elucidated by ROSSOR et al. [104] in a crossover study in term
neonates. The authors found no difference in carbon dioxide sensitivity between the prone and supine
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positions, but a significantly longer time constant for the carbon dioxide response in prone sleep,
indicating a damped ventilatory response to hypercarbia. BARIKBIN et al. [105] in a study of infants with
congenital cystic adenomatoid malformations of the lung found that a breathing pattern consistent with a
more severe restrictive ventilation disorder, in particular, reduced respiratory compliance, was associated
with the need for surgery during the first 2 years of life, thus showing that lung function testing may be an
important tool for monitoring and guiding treatment of infants with this rare condition.
Paediatric intensive care
There is much interest in noninvasive respiratory support for children with moderate to severe acute onset
of respiratory distress. The use of high-flow nasal cannula (HFNC) oxygen therapy has expanded
dramatically over the past few years. In a retrospective study, RUBIO et al. [91] reported that HFNC provided
a safe and effective means of respiratory support for children with viral bronchiolitis in a secondary
hospital, and that the introduction of HFNC was associated with a 58% reduction in transfers to the
paediatric intensive care unit over two seasons. HFNC has also been successfully used during emergency
transport, as shown by IGLESIAS et al. [106]. HFNC was well tolerated during transport and reduced the need
for continuous positive airway pressure. LUCIANI et al. [107], in a crossover study, found that breathing
efforts decreased significantly more after HFNC than after low-flow oxygen therapy. FOUZAS et al. [108]
presented data from a simulation model they had developed including a new equation to estimate the
effective oxygen delivery in relation to flow and respiratory rate more accurately. In summary, accumulating
evidence implies that HFNC has physiological benefits but larger randomised trials are warranted [109].
Severe acute asthma continues to be a life-threatening condition in children. In a randomised controlled
trial in children 1–12 years of age, TIWARI et al. [110] compared ketamine with aminophylline as second
line adjuvant therapy and found both drugs equally effective. THOUVENIN et al. [111] in a retrospective
review following the publication of the GINA recommendations in 2011 showed that intravenous
magnesium sulfate, if used within the first hour as recommended by GINA, significantly reduced both the
total duration of hospitalisation and the length of stay in the paediatric intensive care unit. This is in
accordance with a very recent systematic review that recommends the use of intravenous magnesium
sulfate as a safe and effective adjunct to conventional bronchodilator therapy in children with acute severe
asthma [112]. Some researchers even believe that the accumulating evidence confirming a favourable “cost
benefit” profile justifies using magnesium for all children presenting with acute severe asthma [113].
Paediatric respiratory epidemiology
Early-life factors for respiratory disorders
Longitudinal birth cohort studies have identified a number of early risk factors for respiratory disorders in
childhood as well as protective factors [114]. Several studies have reported an increased risk of wheezing
and asthma development in children after prenatal exposure to antibiotics [115]. The suggested
mechanism is a derangement in neonatal and infant microbial colonisation patterns. Whether the
association between maternal antibiotics during pregnancy and wheezing or asthma in the offspring is
causal or due to confounding factors has been explored in a cohort study by POPOVIC et al. [116]. and in a
crossover and a case–control study by MULDER et al. [117]. Both studies found an increased risk of
wheezing or asthma for antibiotic prescription in the third trimester of pregnancy but could not rule out
unmeasured confounding as a possible explanation. In particular, in the Italian cohort study [116], the
association greatly diminished after a statistical analysis controlling for several maternal factors. A recent
study using data from the Danish national register found an association between maternal use of
antibiotics and asthma in the offspring regardless of the timing for maternal antibiotic treatment (either
during or before or after pregnancy) [118]. These results are also in favour of a confounding effect due to
a maternal or offspring propensity to infections.
Another topic of interest is vitamin D deficiency in pregnancy and early childhood and the development
of infections or wheezing or asthma in the first years of life. Findings from several cohort studies suggest a
protective effect of 25-hydroxyvitamin D levels both in pregnancy and in childhood against respiratory
infections [119, 120] whereas evidence on protection against wheezing and asthma is inconclusive. In a
case–control study, INGHAM et al. [121] reported an association between vitamin D deficiency and severity
of acute respiratory infections in New Zealand children.
Few data are available on how exposure to air pollution in pregnancy influences respiratory health in
offspring. A recent study in the INMA cohort found an association between prenatal exposure to
residential traffic-related air pollution and lung function deficits at preschool age [122]. Conversely,
OLLSON et al. [38], in a Swedish register-based cohort study, showed no association between nitrogen
dioxide levels at the place of residence during pregnancy or infancy and prescribed asthma medication
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during the sixth year of life. Nitrogen dioxide levels had been evaluated with a dispersion model and used
as an indicator of motor vehicle exhaust.
The role of allergen exposure in causing asthma remains highly debatable [123]. In a collaborative study of
five birth cohorts in Europe, CASAS et al. [124] found a geographical variation in the concentration of
house dust mite in infants’ homes, with lower levels in colder areas, such as Scandinavian regions, and
higher levels in more humid and warm areas, such as the Mediterranean regions. No association was
found with subsequent asthma up to the age of 10 years.
Preterm birth
A recent systematic review and meta-analysis showed that preterm-born survivors, even those in whom
BPD does not develop, have moderate deficits in FEV1 compared with term-born controls [125]. DUIJTS
et al. [39] examined the association between preterm birth and low birth weight with lung function at age
4–18 years, using data from 24715 children in 24 European birth cohorts. Random-effect meta-analyses
were used with individual participant data and pooled effect estimates. The strongest independent effects
were found for preterm birth (<37 versus ⩾37 weeks of gestation) on FEV1/FVC and FEF75% and for low
birth weight (<2500 versus ⩾2500 g) on FEV1, FVC and FEF25–75% (p<0.05). FAINARDI et al. [126], in a
small group of 7-year-old children born very preterm (<32 weeks of gestation), assessed lung function by
IOS. Compared with preterm children born appropriate for gestational age (AGA), children born small for
gestational age or AGA with intrauterine growth restriction showed higher small-airway resistance and
lower pulmonary compliance.
EDWARDS et al. [127], in a large cross-sectional survey of all surviving preterm-born children in Wales
(n=13361) and matched term control children, confirmed previous findings that preterm birth increases
the risk of wheezing disorders [128]. Both the <5-year-old and 5–10-year-old preterm born children in the
RANOPS had higher reported rates of wheezing ever, wheeze in the last 3 months and use of inhaled
medication than term infants. Analysis by gestational age showed a gradient of increasing respiratory
symptoms and use of inhaled medication for each week of gestational age prior to 38 weeks.
Primary ciliary dyskinesia
A number of national and international databases have been developed in order to better define clinical
and laboratory data of paediatric PCD. MAURER et al. [129] presented preliminary data from a large
multinational dataset (2128 patients in 16 countries, in the framework of the European Union Seventh
Framework project BESTCILIA); THOUVENIN et al. [130], data from a French national cohort (298 patients
in 23 centres); and SNIJDERS et al. [131], data from an Italian survey (261 patients in 21 centres). The latter
group reported that age at diagnosis in patients <18 years was 5.0 years lower in children with situs
inversus (4.2 versus 6.0 years, p<0.0127) and higher in children with bronchiectasis (7.0 versus 3.5 years,
p<0.0001). GOUTAKI et al. [132] assessed height and BMI in 263 paediatric and adult patients with PCD
from six different centres (BESTCILIA project) and found comparable height z-scores and slightly higher
BMI z-scores compared with World Health Organization reference data, suggesting that undernutrition
might not be a predominant problem in PCD. In a study presenting 5-year data on re-testing in 162
patients diagnosed with PCD across a broad range of phenotypic variants, HIRST et al. [133] showed that
inner dynein arm phenotypic variants in the cilia of PCD can in some cases revert to normal on
re-testing. They concluded that re-testing for PCD should be considered in patients whose initial biopsy
suggested an absence of inner dynein arms.
Paediatric bronchology
Bronchoscopy is a well-established and standardised technique. Many groups are now looking at the
paediatric bronchoscope as an interventional tool, especially in congenital anomalies and airway narrowing.
In a retrospective study of 61 children with endoscopic findings of vascular anomalies causing
compression of the tracheobronchial tree, SERIO et al. [134] found a good agreement between
bronchoscopy and CT angiography. The same group recently published follow-up data for a series of 100
consecutive children who underwent stent insertion for airway narrowing of various aetiologies [135].
They had inserted 235 airway stents with no fatal complications and 80% of the patients had experienced
significant improvement. ANTON-PACHECO et al. [136] presented their initial experience with biodegradable
polydioxanone stents in two infants (5 and 8 months of age) with severe airway narrowing (fig. 4).
Although one child had to undergo multiple stent insertions, no intervention led to stent-related
complications, such as stent displacement, bleeding, granulation tissue formation or perforation during the
2-year follow-up. This group has already published information on the use of biodegradable stents in
children after slide tracheoplasty, reporting the technique’s good safety profile [137]. Although
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biodegradable stents seem to be a very promising alternative to metallic or silicone stents, more experience
is needed to define the precise indications in children.
MADKOUR et al. presented their experience with the use of a laryngeal mask airway (LMA) for foreign body
extraction with a flexible bronchoscope [138]. In a prospective 1-year study, they included 49 children
(mean age 5.9 years) suspected of having aspirated a foreign body. They identified 41 mainly organic
foreign bodies and successfully removed 34 (82.9%). In six cases they had to use a rigid bronchoscope and
ultimately removed one foreign body via open thoracotomy. The authors reported no critical
complications related to flexible bronchoscopy. They concluded that the main advantage of the LMA is
that larger (adult size) flexible bronchoscopes and, thus, larger extraction forceps may be used. This study
adds to the growing evidence showing that flexible bronchoscopy may be a feasible technique for
extracting foreign bodies in children.
MORENO et al. [139] addressed the association of protracted bacterial bronchitis (PBB) and airway malacia.
They retrospectively analysed data of 165 children who underwent bronchoscopy for persistent cough and
received a final diagnosis of PBB or airway malacia. The average age at diagnosis of PBB was 3 years. In 53
children with PBB, only 10 had no symptoms indicating airway malacia. Airway malacia was associated
with poor response to treatment and the authors concluded that patients with PBB and malacia should
probably receive prolonged antibiotic treatment. Several papers in recent years have looked at bacterial
bronchitis and airway malacia [140, 141]. Children with clinically diagnosed PBB should undergo
bronchoscopy to document possible airway malacia, a factor that potentially can contribute to disease
severity and to poor response to treatment.
GOUSSARD et al. [142], in children with tuberculosis (TB), studied the use of GeneXpert MTB/RIF
(Cepheid, Sunnyvale, CA, USA) testing on bronchoalveolar lavage (BAL) fluid. Among 40 children
(median age 18 months), TB was confirmed in 29 (73%) by Xpert and 23 (58%) by culture. In 21 (53%)
children both methods yielded positive results. Positive Xpert testing was associated with lymph nodes
FIGURE 4 Bronchoscopic view 15 weeks after polydioxanone tracheal stent insertion. Reproduced from [136] with
permission from the authors.
ERJ Open Res 2015; 1: 00016–2015 | DOI: 10.1183/23120541.00016-2015 13
PAEDIATRICS | F. MIDULLA ET AL.
ulcerating into the airway (p=0.03), lung disease on chest X-ray or duration of treatment <14 days.
Because median time to culture positivity in this group was 14 days, methods such as Xpert can speed-up
the diagnostic workup and increase the diagnostic yield.
SVEDBERG et al. [143] looked at BAL fluid return and factors that may influence the amount of BAL fluid
recovered from the bronchial tree. In 311 children who underwent bronchoscopy and BAL for diagnostic
purposes, they found that younger age and higher percentage of neutrophils were associated with reduced
BAL fluid return.
HONKOVÁ et al. [144] presented new data on bronchial remodelling. They did bronchial biopsies in 27
children with asthma, 15 with CF and 14 with PCD, and compared basement membrane (BM) thickness
and the deposition of structural proteins (tenascin C and collagen IV) in patients and seven controls. In
contrast to earlier opinions, this study found similar airway remodelling in all studied chronic respiratory
diseases. No difference was found in BM thickness and tenascin layer between children with asthma, CF or
PCD. These data add new knowledge about airway remodelling in asthma [145, 146].
KRIVEC et al. [147] studied the role of bronchoscopy in children with neuromuscular diseases (NMDs) and
acute hypoxaemic respiratory failure requiring noninvasive ventilation. In eight consecutive children
(median age 3.2 years) with NMD, lower respiratory infections and atelectasis, the authors used a specific
protocol consisting of flexible bronchoscopy for airway suction (six children), noninvasive ventilation
(eight children) and physiotherapy with a cough-assist device (eight children). In all the children who
underwent full treatment including bronchoscopy, but not in two who only had noninvasive ventilation
and physiotherapy, atelectasis fully resolved. This small series supports the idea of using flexible
bronchoscopy for managing respiratory complications in NMD.
ARUMUGAM et al. [148] in 53 children with difficult asthma, cystic fibrosis and chronic cough studied the
diagnostic value of the lipid-laden macrophage index (LLMI) in BAL fluid. Comparing oesophageal pH or
impedance with symptoms and LLMI, they found that neither technique achieved sufficient diagnostic
sensitivity and specificity in detecting acidic or nonacidic gastro-oesophageal reflux-related pulmonary
aspiration in children with respiratory problems. JEDYNAK-WASOWICZ et al. [149] studied the extraoesophageal
reflux by monitoring oropharyngeal reflux in 21 children with chronic cough and observed that in coughing
children, reflux events detected by standard multichannel intraluminal impedance/pH measurement and
oropharyngeal pH monitoring correlated only when subjects were examined in the supine position. This
interesting observation merits further studies because it could influence current diagnostic standards.
UMUTOGLU et al. [150], in a randomised, controlled, crossover study of patients aged between 0 and 15 years
of age, compared various manoeuvres used for visualising the glottis during flexible bronchoscopy. They
found that the most effective manoeuvres were the head tilt, chin lift and triple-airway manoeuvres.
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